SlideShare una empresa de Scribd logo
1 de 30
Long-Term Treatment for Severe Alopecia
Areata with Oral Tofacitinib Citrate
Melissa Piliang, MD, FAAD
Dermatology and Pathology
Cleveland Clinic
Allergan
Incyte
Conflict of interest
Concert
Samumed
Allergan
P&G
Co-authors
Wilma Bergfeld, MD
Sara Hogan, MD
What’s New in Alopecia Areata
Killing two birds with one stone
Images obtained via Google, in public domain
25 year old man
Alopecia areata since childhood
Alopecia universalis for 7 years
Psoriasis
The case that stirred an interest in Jak I
JAK-Inhibitors
Experience with JAK inhibitors for Alopecia
Areata
OralTofactinib + AA: Cleveland Clinic Experience
2015-2018
• Retrospective, open-label
• 20 patients
• Mostly female (90%)
• More likely to have:
- Thyroid disease (65%)
- Atopy (40%)
- Many had autoimmune comorbitities
• RA, psoriasis
OralTofactinib + AA: Cleveland Clinic Experience
2015-2018
• Severe disease:
- Alopecia universalis - 70%
- Alopecia totalis - 20%
- Mean baseline SALT score - 88%
• Average length of current episode of
alopecia was 2.4 years
Doses ranged from 10-30 mg daily (most: 20 mg daily, divided dosing)
2017 analysis
Overall, majority of patients experienced some form of regrowth
47% had regrowth by 12 months
• Regrowth independent of
• age
• disease severity
• disease duration
• minimal side effect
JAMA Dermatol, 2017 Jun 153(6): 600-602
Oral Tofactinib + AA: Cleveland Clinic Experience
2015-2016
Long Term Use of Tofactinib for AA
Cleveland Clinic
2018 analysis
Baseline moderate to severe AA (n=20)
• Doses 10-30 mg daily
• 13/20 patients taking tofacitinib for over 12 months
• 30% with disease duration >20 years
• 12% with nail involvement
• 14/20 (70%) experienced hair regrowth by month 3
• 94% had regrowth by month 9 and 12
• SALT scores at month 3, 9, 12 months significantly lower than baseline
• 11/12 of patients on Tofa >12 months still with regrowth
• 3/12 (25%) with nail involvement had improvement
• Also noted by month 3
CC: Alopecia Universalis
HPI: 56 year old woman
• 23 year history of alopecia universalis
• Last notable hair growth was 19 years ago
• Previous Treatments
• Topical and intralesional corticosteroids
• Pimecrolimus
• Anthralin
• Diphenylcyclopropenone
• Methotrexate
• Numerous nutritional supplements
Past Medical History:
• Hashimoto’s thyroiditis on levothyroxine
• Hyperlipidemia
• Iron deficiency anemia
Physical Exam
• Complete loss of scalp hair,
eyelashes, eyebrows, body hair
- SALT score of 100
• Pitting and trachonychia of all
fingernails and toenails
Patient Course
Started
medication
5 mg BID
Nov 2015
First hair
growth
10 mg BID
Jan 2016
SALT 22
May 2016
Complete
regrowth
April 2017
Regrowth
maintained
November 2018
April 2016
Herpes
zoster
May 2018
Influenza A
SALT 100
Labs
CBC with differential
Peripheral eosinophilia (0.54)
May 2017: resolved (0.37)
December 2017: remains within normal limits (0.07)
CMP within normal limits
Lipid panel
Initiation, hypercholesterolemia: (Cholesterol 217, Triglyceride 147, LDL 143)
August 2016: hypertriglyceridemia (Cholesterol 250, Triglyceride 288, LDL 153)
September 2016: started on atorvastatin
September 2017: improved (Cholesterol 151, Triglyceride 178, LDL 68)
Patient #3
Baseline Month 16 Month 22 Month 30
Patient #9
Baseline Month 9 Month 12 Month 20
Patient #14
Baseline Month 3 Month 9 Month 24
Moderate Response
Pre Post
Dose: 5 mg BID
Duration of therapy: 3.5
mos
Age: 44
Duration of disease: 34 yrs
Mild Response
Cose: 10 mg BID (20 mg) – has been as high as 15 mg BID
Duration of therapy: 20 mo
Age: 53
Duration of disease: 10 yrs
Pre 18 Months10 Months
Minimal Response
Dose: 10 mg BID
Duration of therapy: 7 mo
Age: 61
Duration of disease: 5 yrs
Pre Post
No response
Dose: 10 mg BID
Duration of therapy: 7 mos
Age: 55
Duration of disease: 7 yrs
Pre Post
Current dose: 5 mg BID
Duration of therapy: 6 mos
Age: 53
Duration of disease: 30 yrs
Excellent response No response
Pre Month 6Month 5
What Happened?
Month 5
Month 6
1. She lost coverage -> off Jak I for several
weeks
2. Vit D was low
3. She was hypothyroid
-> levothyroxine dose change
Patien
t #
Se
x
Age at
treatment
initiation
Disease
duration
(years
since
diagnosis
of AA)
Time
since
last hair
growth
(years)
Months
until first
signs of
hair
growth
Duration
of
therapy
(months)
Holding
dose
(mg/day,
split
twice
daily)
SALT score
at
treatment
initiation
SALT
score at
final data
collection
Percent
regrowth
at time of
last
appointme
nt
1 F 50s 25 1 3 22 20 100 30.8 69%
2 F 40s 19 4 3 15 20 78.3 32.2 59%
3 F 20s 16 3 17 15 100 50.6 49%
4 F 50s 26 4 7 28 15 100 44.8 50%
5 F 30s 13 1 0 0.5 10 95 44 50%
6 F 50s 16 2 10 26 20 100 95 5%
7 F 60s 7 1 3 7 20 100 95 5%
8 F 40s 36 3 3 3 10 79.3 44.2 40%
9 F 50s 15 1 12 20 76 3 96%
10 F 30s 9 3 4 15 10 100 98 2%
11 F 50s 9 7 8 24 20 100 20 80%
12 F 50s 31 1 3 6 10 100 1 99%
13 F 50s 1 6 20 10 95 0 100%
14 F 30s 7 1 1 12 20 50 0 100%
15 F 50s 11 1 2 25 25 71.6 38 47%
16 M 20s 5
2
3 4 10 100
100 0%
“scant”
17 M 50s 3 2 2 12 20 100 50 50%
18 F 50s 16 6 2 5 10 90 47.2 48%
19 F 40s 17 8 13 10 50 0 100%
20 F 60s 44 1 3 4 10 100 100 10%
• 20 yo
• Psoriasis and PsA
1 month
5 mg bid
5 month
10 mg bid
7 month
10 mg bid
10 months
15 mg bid
Psoriasis improved
Psoriatic arthritis
persisted
• 15 months
• 15 mg bid
• PsO/PsA flared
• No change or
disruption in dose
• No obvious reason
Durability with Long-Term Tofacitinib for AA
• 6 patients experienced medication interruption
• Adverse effect, illness, lapse in insurance coverage
• 4/6 (66%) with medication interruption
experienced shedding
• Noted within 4 weeks
• Resuming Tofacitinib after interruption had
stabilization of shedding within 1-2 months
• 2/20 discontinued due to adverse reactions
Tolerability with Long-Term Tofacitinib for AA
• LFT elevation (2/20) 10%
• Resolved with dose adjustment in 1, the other had to stop
tofa
• Hypercholesterolemia (3/20) 15%
• Noted by month 4 of treatment
• Slower to respond with dose adjustment
• Other:
• Lower Extremity Edema (1/20) 5%: medication
discontinued
• Palpitations (1/20) 5%: found to be hyperthyroid
• Leukopenia (1/20) 5%: transient
• Herpes reactivation (1/20) 5%
Safe but close monitoring (every 3-4 months) important
Summary Tofacitinib Long Term Data
• Results:
- 75% achieved some regrowth
- 60% - SALT50
- 25% - SALT90 (essentially fully regrowth)
- 30-40% - insufficient or no response
• Poor responders
- Increase to 15-20 mg daily
• Less likely to respond:
- Longer duration of episode (>10 years)
• Durability – 2 months post discontinuation –
shedding
Take Home Points
• This is a very exciting time for alopecia areata!
The era of biologic treatment of AA is just beginning
- Future
• More options- precision targeted therapy
• Better
• Safer
• More affordable (hopefully)
Support National Alopecia Areata Foundation (NAAF)
Thank you!

Más contenido relacionado

La actualidad más candente

Biologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenariosBiologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenariosSandeep Lal V
 
Biologicals in Deramtology (Part 1 )
Biologicals in Deramtology (Part 1 )Biologicals in Deramtology (Part 1 )
Biologicals in Deramtology (Part 1 )Smruti Ramawanshi
 
Fractional radiofrequency microneedling in esthetic medicine
Fractional radiofrequency microneedling in esthetic medicineFractional radiofrequency microneedling in esthetic medicine
Fractional radiofrequency microneedling in esthetic medicinepeternugraha
 
Treatment of psoriasis
Treatment of psoriasisTreatment of psoriasis
Treatment of psoriasisAsafAldoury
 
Epidermal kinetics
Epidermal kineticsEpidermal kinetics
Epidermal kineticsRohit Singh
 
Minoxidil - Translation from Hypertension ingredient to Hair Growth Stimulant
Minoxidil - Translation from Hypertension ingredient to Hair Growth StimulantMinoxidil - Translation from Hypertension ingredient to Hair Growth Stimulant
Minoxidil - Translation from Hypertension ingredient to Hair Growth StimulantKumar Organic Products Ltd
 
Seminar principles of topical therapy
Seminar principles of topical therapySeminar principles of topical therapy
Seminar principles of topical therapyDr Daulatram Dhaked
 
Newer drugs used in leprosy
Newer drugs used in leprosyNewer drugs used in leprosy
Newer drugs used in leprosyAnil Kumar B C
 

La actualidad más candente (20)

Biologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenariosBiologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenarios
 
Tofacitinib.ppt
Tofacitinib.pptTofacitinib.ppt
Tofacitinib.ppt
 
Atopic dermatitis
Atopic dermatitisAtopic dermatitis
Atopic dermatitis
 
Atopic-Derm-CME_Slides.pptx
Atopic-Derm-CME_Slides.pptxAtopic-Derm-CME_Slides.pptx
Atopic-Derm-CME_Slides.pptx
 
Retinoids
RetinoidsRetinoids
Retinoids
 
Biologicals in Deramtology (Part 1 )
Biologicals in Deramtology (Part 1 )Biologicals in Deramtology (Part 1 )
Biologicals in Deramtology (Part 1 )
 
Acne Vulgaris
Acne VulgarisAcne Vulgaris
Acne Vulgaris
 
Morphea
MorpheaMorphea
Morphea
 
Cyclosporine in dermatology
Cyclosporine in dermatologyCyclosporine in dermatology
Cyclosporine in dermatology
 
Melasma treatment
Melasma treatmentMelasma treatment
Melasma treatment
 
Fractional radiofrequency microneedling in esthetic medicine
Fractional radiofrequency microneedling in esthetic medicineFractional radiofrequency microneedling in esthetic medicine
Fractional radiofrequency microneedling in esthetic medicine
 
Atopic dermatitis: mechanism of disease
Atopic dermatitis: mechanism of diseaseAtopic dermatitis: mechanism of disease
Atopic dermatitis: mechanism of disease
 
Treatment of psoriasis
Treatment of psoriasisTreatment of psoriasis
Treatment of psoriasis
 
Epidermal kinetics
Epidermal kineticsEpidermal kinetics
Epidermal kinetics
 
Minoxidil - Translation from Hypertension ingredient to Hair Growth Stimulant
Minoxidil - Translation from Hypertension ingredient to Hair Growth StimulantMinoxidil - Translation from Hypertension ingredient to Hair Growth Stimulant
Minoxidil - Translation from Hypertension ingredient to Hair Growth Stimulant
 
Nutrophilic dermatosis
Nutrophilic dermatosisNutrophilic dermatosis
Nutrophilic dermatosis
 
Apremilast
ApremilastApremilast
Apremilast
 
Seminar principles of topical therapy
Seminar principles of topical therapySeminar principles of topical therapy
Seminar principles of topical therapy
 
Acne
AcneAcne
Acne
 
Newer drugs used in leprosy
Newer drugs used in leprosyNewer drugs used in leprosy
Newer drugs used in leprosy
 

Similar a Long Term Treatment for Severe Alopecia Areata with Oral Tofacitinib Citrate

Pediatric Alopecia Areata: What's New in Management, Treatment and Education
Pediatric Alopecia Areata: What's New in Management, Treatment and EducationPediatric Alopecia Areata: What's New in Management, Treatment and Education
Pediatric Alopecia Areata: What's New in Management, Treatment and EducationNational Alopecia Areata Foundation
 
Recent Advances in Alopecia Areata.pptx
Recent Advances in Alopecia Areata.pptxRecent Advances in Alopecia Areata.pptx
Recent Advances in Alopecia Areata.pptxPawanMandiwal1
 
Management of Epilepsy
Management of EpilepsyManagement of Epilepsy
Management of EpilepsyBhupendra Shah
 
Autoimmune Hepatitis-update-2021 powerpoint
Autoimmune Hepatitis-update-2021 powerpointAutoimmune Hepatitis-update-2021 powerpoint
Autoimmune Hepatitis-update-2021 powerpointssuser4ddc5d
 
PML - patient case study - Sharon Letissier
PML - patient case study - Sharon LetissierPML - patient case study - Sharon Letissier
PML - patient case study - Sharon LetissierMS Trust
 
5 lacerda liver disease
5 lacerda liver disease5 lacerda liver disease
5 lacerda liver diseaseangel4567
 
Post-radiotherapy Endocrine Effects
Post-radiotherapy Endocrine EffectsPost-radiotherapy Endocrine Effects
Post-radiotherapy Endocrine EffectsPeninsulaEndocrine
 
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...Lifecare Centre
 
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...Jarrod Lee
 
New and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesNew and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesVisionary Ophthamology
 
What's New in Research: Genetics & immunology of Alopecia Areata
What's New in Research: Genetics & immunology of Alopecia AreataWhat's New in Research: Genetics & immunology of Alopecia Areata
What's New in Research: Genetics & immunology of Alopecia AreataNational Alopecia Areata Foundation
 
MAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAMAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAspa718
 

Similar a Long Term Treatment for Severe Alopecia Areata with Oral Tofacitinib Citrate (20)

NAAF and Research: Patient Engagement
NAAF and Research: Patient EngagementNAAF and Research: Patient Engagement
NAAF and Research: Patient Engagement
 
Pediatric Alopecia Areata: What's New in Management, Treatment and Education
Pediatric Alopecia Areata: What's New in Management, Treatment and EducationPediatric Alopecia Areata: What's New in Management, Treatment and Education
Pediatric Alopecia Areata: What's New in Management, Treatment and Education
 
Seminar: HOMOEOPATHIC MANAGEMENT OF HIV/AIDS
Seminar: HOMOEOPATHIC MANAGEMENT OF HIV/AIDSSeminar: HOMOEOPATHIC MANAGEMENT OF HIV/AIDS
Seminar: HOMOEOPATHIC MANAGEMENT OF HIV/AIDS
 
Recent Advances in Alopecia Areata.pptx
Recent Advances in Alopecia Areata.pptxRecent Advances in Alopecia Areata.pptx
Recent Advances in Alopecia Areata.pptx
 
Chronic spontaneous urticaria (part 1)
Chronic spontaneous urticaria (part 1)Chronic spontaneous urticaria (part 1)
Chronic spontaneous urticaria (part 1)
 
Management of Epilepsy
Management of EpilepsyManagement of Epilepsy
Management of Epilepsy
 
Autoimmune Hepatitis-update-2021 powerpoint
Autoimmune Hepatitis-update-2021 powerpointAutoimmune Hepatitis-update-2021 powerpoint
Autoimmune Hepatitis-update-2021 powerpoint
 
PML - patient case study - Sharon Letissier
PML - patient case study - Sharon LetissierPML - patient case study - Sharon Letissier
PML - patient case study - Sharon Letissier
 
5 lacerda liver disease
5 lacerda liver disease5 lacerda liver disease
5 lacerda liver disease
 
Translating advances in therapeutics to pediatrics
Translating advances in therapeutics to pediatricsTranslating advances in therapeutics to pediatrics
Translating advances in therapeutics to pediatrics
 
Ppt
PptPpt
Ppt
 
Platinum hypersensitivity
Platinum hypersensitivityPlatinum hypersensitivity
Platinum hypersensitivity
 
Post-radiotherapy Endocrine Effects
Post-radiotherapy Endocrine EffectsPost-radiotherapy Endocrine Effects
Post-radiotherapy Endocrine Effects
 
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...
PANEL DISCUSSION Management Of Adolescent PCOS And Associated Fertility Conc...
 
Everything you need to know about alopecia areata
Everything you need to know about alopecia areataEverything you need to know about alopecia areata
Everything you need to know about alopecia areata
 
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...
Helicobacter Pylori & Gastric Cancer - An Evidence Based Approach for Primary...
 
New and emerging therapies for retinal diseases
New and emerging therapies for retinal diseasesNew and emerging therapies for retinal diseases
New and emerging therapies for retinal diseases
 
Treatment of Alopecia Areata: Overview
Treatment of Alopecia Areata: OverviewTreatment of Alopecia Areata: Overview
Treatment of Alopecia Areata: Overview
 
What's New in Research: Genetics & immunology of Alopecia Areata
What's New in Research: Genetics & immunology of Alopecia AreataWhat's New in Research: Genetics & immunology of Alopecia Areata
What's New in Research: Genetics & immunology of Alopecia Areata
 
MAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMAMAINTENANCE THERAPY IN MULTIPLE MYELOMA
MAINTENANCE THERAPY IN MULTIPLE MYELOMA
 

Más de National Alopecia Areata Foundation

What's New in Research: Genetics and Immunology of Alopecia Areata
What's New in Research: Genetics and Immunology of Alopecia AreataWhat's New in Research: Genetics and Immunology of Alopecia Areata
What's New in Research: Genetics and Immunology of Alopecia AreataNational Alopecia Areata Foundation
 
Epidemiologic association between atopic dermatitis and alopecia areata
Epidemiologic association between atopic dermatitis and alopecia areataEpidemiologic association between atopic dermatitis and alopecia areata
Epidemiologic association between atopic dermatitis and alopecia areataNational Alopecia Areata Foundation
 
The evolving pathogenesis of alopecia areata and biomarkers of disease
The evolving pathogenesis of alopecia areata and biomarkers of diseaseThe evolving pathogenesis of alopecia areata and biomarkers of disease
The evolving pathogenesis of alopecia areata and biomarkers of diseaseNational Alopecia Areata Foundation
 
The atopic dermatitis pathogenesis and implications for alopecia areata
The atopic dermatitis pathogenesis and implications for alopecia areataThe atopic dermatitis pathogenesis and implications for alopecia areata
The atopic dermatitis pathogenesis and implications for alopecia areataNational Alopecia Areata Foundation
 
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...National Alopecia Areata Foundation
 
Broadening Diversity in Alopecia Areata Clinical Trial Participants
Broadening Diversity in Alopecia Areata Clinical Trial ParticipantsBroadening Diversity in Alopecia Areata Clinical Trial Participants
Broadening Diversity in Alopecia Areata Clinical Trial ParticipantsNational Alopecia Areata Foundation
 
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...National Alopecia Areata Foundation
 
The Role of Patients in the Development of the Alopecia Areata Investigator G...
The Role of Patients in the Development of the Alopecia Areata Investigator G...The Role of Patients in the Development of the Alopecia Areata Investigator G...
The Role of Patients in the Development of the Alopecia Areata Investigator G...National Alopecia Areata Foundation
 

Más de National Alopecia Areata Foundation (20)

What's New in Research: Genetics and Immunology of Alopecia Areata
What's New in Research: Genetics and Immunology of Alopecia AreataWhat's New in Research: Genetics and Immunology of Alopecia Areata
What's New in Research: Genetics and Immunology of Alopecia Areata
 
NAAF Scientific Update
NAAF Scientific UpdateNAAF Scientific Update
NAAF Scientific Update
 
Therapeutic advances in alopecia areata
Therapeutic advances in alopecia areataTherapeutic advances in alopecia areata
Therapeutic advances in alopecia areata
 
The therapeutic landscape in atopic dermatitis
The therapeutic landscape in atopic dermatitisThe therapeutic landscape in atopic dermatitis
The therapeutic landscape in atopic dermatitis
 
Epidemiologic association between atopic dermatitis and alopecia areata
Epidemiologic association between atopic dermatitis and alopecia areataEpidemiologic association between atopic dermatitis and alopecia areata
Epidemiologic association between atopic dermatitis and alopecia areata
 
The evolving pathogenesis of alopecia areata and biomarkers of disease
The evolving pathogenesis of alopecia areata and biomarkers of diseaseThe evolving pathogenesis of alopecia areata and biomarkers of disease
The evolving pathogenesis of alopecia areata and biomarkers of disease
 
The atopic dermatitis pathogenesis and implications for alopecia areata
The atopic dermatitis pathogenesis and implications for alopecia areataThe atopic dermatitis pathogenesis and implications for alopecia areata
The atopic dermatitis pathogenesis and implications for alopecia areata
 
Genetics, Immunology and Therapeutic Targets Breakout Report
Genetics, Immunology and Therapeutic Targets Breakout ReportGenetics, Immunology and Therapeutic Targets Breakout Report
Genetics, Immunology and Therapeutic Targets Breakout Report
 
Health Economics and Burden of Disease Breakout Report
Health Economics and Burden of Disease Breakout ReportHealth Economics and Burden of Disease Breakout Report
Health Economics and Burden of Disease Breakout Report
 
Clinical Outcome Assessments Breakout Report
Clinical Outcome Assessments Breakout ReportClinical Outcome Assessments Breakout Report
Clinical Outcome Assessments Breakout Report
 
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...
Alopecia Areata: Autoimmune Disease or Hair Follicle Response Pattern to Immu...
 
Broadening Diversity in Alopecia Areata Clinical Trial Participants
Broadening Diversity in Alopecia Areata Clinical Trial ParticipantsBroadening Diversity in Alopecia Areata Clinical Trial Participants
Broadening Diversity in Alopecia Areata Clinical Trial Participants
 
Willingness to Pay and Quality of Life in Alopecia Areata
Willingness to Pay and Quality of Life in Alopecia AreataWillingness to Pay and Quality of Life in Alopecia Areata
Willingness to Pay and Quality of Life in Alopecia Areata
 
Rare Genetic Mutations Contribute to Alopecia Areata Etiology
Rare Genetic Mutations Contribute to Alopecia Areata EtiologyRare Genetic Mutations Contribute to Alopecia Areata Etiology
Rare Genetic Mutations Contribute to Alopecia Areata Etiology
 
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...
SSEA-Positive Myeloid Cells are Involved in Hair Loss in the Alopecia Areata ...
 
The Role of Patients in the Development of the Alopecia Areata Investigator G...
The Role of Patients in the Development of the Alopecia Areata Investigator G...The Role of Patients in the Development of the Alopecia Areata Investigator G...
The Role of Patients in the Development of the Alopecia Areata Investigator G...
 
2018 Alopecia Areata Research Summit: Summary of First Day
2018 Alopecia Areata Research Summit: Summary of First Day2018 Alopecia Areata Research Summit: Summary of First Day
2018 Alopecia Areata Research Summit: Summary of First Day
 
NAAF Patient-Reported Outcomes Consortium
NAAF Patient-Reported Outcomes ConsortiumNAAF Patient-Reported Outcomes Consortium
NAAF Patient-Reported Outcomes Consortium
 
Standardizing Outcome Measures in Alopecia Areata
Standardizing Outcome Measures in Alopecia AreataStandardizing Outcome Measures in Alopecia Areata
Standardizing Outcome Measures in Alopecia Areata
 
Legacy Healthcare and Alopecia Areata Program Overview
Legacy Healthcare and Alopecia Areata Program OverviewLegacy Healthcare and Alopecia Areata Program Overview
Legacy Healthcare and Alopecia Areata Program Overview
 

Último

7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana GuptaLifecare Centre
 
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service AvailableDipal Arora
 
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Sheetaleventcompany
 
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Sheetaleventcompany
 
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...Sheetaleventcompany
 
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...rajnisinghkjn
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...gragneelam30
 
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...Sheetaleventcompany
 
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...call girls hydrabad
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxSwetaba Besh
 
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...Sheetaleventcompany
 
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...amritaverma53
 
tongue disease lecture Dr Assadawy legacy
tongue disease lecture Dr Assadawy legacytongue disease lecture Dr Assadawy legacy
tongue disease lecture Dr Assadawy legacyDrMohamed Assadawy
 
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book nowChennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book nowtanudubay92
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan 087776558899
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsMedicoseAcademics
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...Sheetaleventcompany
 
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...Sheetaleventcompany
 
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...Sheetaleventcompany
 
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationCardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationMedicoseAcademics
 

Último (20)

7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
 
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service AvailableCall Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
Call Girls Kathua Just Call 8250077686 Top Class Call Girl Service Available
 
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
 
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
 
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
❤️Call Girl Service In Chandigarh☎️9814379184☎️ Call Girl in Chandigarh☎️ Cha...
 
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
 
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...
❤️Amritsar Escorts Service☎️9815674956☎️ Call Girl service in Amritsar☎️ Amri...
 
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
 
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
Premium Call Girls Nagpur {9xx000xx09} ❤️VVIP POOJA Call Girls in Nagpur Maha...
 
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
 
tongue disease lecture Dr Assadawy legacy
tongue disease lecture Dr Assadawy legacytongue disease lecture Dr Assadawy legacy
tongue disease lecture Dr Assadawy legacy
 
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book nowChennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book now
Chennai ❣️ Call Girl 6378878445 Call Girls in Chennai Escort service book now
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
 
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
❤️Chandigarh Escorts Service☎️9814379184☎️ Call Girl service in Chandigarh☎️ ...
 
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
Call Girl In Chandigarh 📞9809698092📞 Just📲 Call Inaaya Chandigarh Call Girls ...
 
Cardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their RegulationCardiac Output, Venous Return, and Their Regulation
Cardiac Output, Venous Return, and Their Regulation
 

Long Term Treatment for Severe Alopecia Areata with Oral Tofacitinib Citrate

  • 1. Long-Term Treatment for Severe Alopecia Areata with Oral Tofacitinib Citrate Melissa Piliang, MD, FAAD Dermatology and Pathology Cleveland Clinic Allergan Incyte Conflict of interest Concert Samumed Allergan P&G Co-authors Wilma Bergfeld, MD Sara Hogan, MD
  • 2. What’s New in Alopecia Areata Killing two birds with one stone Images obtained via Google, in public domain 25 year old man Alopecia areata since childhood Alopecia universalis for 7 years Psoriasis The case that stirred an interest in Jak I
  • 3. JAK-Inhibitors Experience with JAK inhibitors for Alopecia Areata
  • 4. OralTofactinib + AA: Cleveland Clinic Experience 2015-2018 • Retrospective, open-label • 20 patients • Mostly female (90%) • More likely to have: - Thyroid disease (65%) - Atopy (40%) - Many had autoimmune comorbitities • RA, psoriasis
  • 5. OralTofactinib + AA: Cleveland Clinic Experience 2015-2018 • Severe disease: - Alopecia universalis - 70% - Alopecia totalis - 20% - Mean baseline SALT score - 88% • Average length of current episode of alopecia was 2.4 years
  • 6. Doses ranged from 10-30 mg daily (most: 20 mg daily, divided dosing) 2017 analysis Overall, majority of patients experienced some form of regrowth 47% had regrowth by 12 months • Regrowth independent of • age • disease severity • disease duration • minimal side effect JAMA Dermatol, 2017 Jun 153(6): 600-602 Oral Tofactinib + AA: Cleveland Clinic Experience 2015-2016
  • 7. Long Term Use of Tofactinib for AA Cleveland Clinic 2018 analysis Baseline moderate to severe AA (n=20) • Doses 10-30 mg daily • 13/20 patients taking tofacitinib for over 12 months • 30% with disease duration >20 years • 12% with nail involvement • 14/20 (70%) experienced hair regrowth by month 3 • 94% had regrowth by month 9 and 12 • SALT scores at month 3, 9, 12 months significantly lower than baseline • 11/12 of patients on Tofa >12 months still with regrowth • 3/12 (25%) with nail involvement had improvement • Also noted by month 3
  • 8. CC: Alopecia Universalis HPI: 56 year old woman • 23 year history of alopecia universalis • Last notable hair growth was 19 years ago • Previous Treatments • Topical and intralesional corticosteroids • Pimecrolimus • Anthralin • Diphenylcyclopropenone • Methotrexate • Numerous nutritional supplements
  • 9. Past Medical History: • Hashimoto’s thyroiditis on levothyroxine • Hyperlipidemia • Iron deficiency anemia
  • 10. Physical Exam • Complete loss of scalp hair, eyelashes, eyebrows, body hair - SALT score of 100 • Pitting and trachonychia of all fingernails and toenails
  • 11. Patient Course Started medication 5 mg BID Nov 2015 First hair growth 10 mg BID Jan 2016 SALT 22 May 2016 Complete regrowth April 2017 Regrowth maintained November 2018 April 2016 Herpes zoster May 2018 Influenza A SALT 100
  • 12. Labs CBC with differential Peripheral eosinophilia (0.54) May 2017: resolved (0.37) December 2017: remains within normal limits (0.07) CMP within normal limits Lipid panel Initiation, hypercholesterolemia: (Cholesterol 217, Triglyceride 147, LDL 143) August 2016: hypertriglyceridemia (Cholesterol 250, Triglyceride 288, LDL 153) September 2016: started on atorvastatin September 2017: improved (Cholesterol 151, Triglyceride 178, LDL 68)
  • 13. Patient #3 Baseline Month 16 Month 22 Month 30
  • 14. Patient #9 Baseline Month 9 Month 12 Month 20
  • 15. Patient #14 Baseline Month 3 Month 9 Month 24
  • 16. Moderate Response Pre Post Dose: 5 mg BID Duration of therapy: 3.5 mos Age: 44 Duration of disease: 34 yrs
  • 17. Mild Response Cose: 10 mg BID (20 mg) – has been as high as 15 mg BID Duration of therapy: 20 mo Age: 53 Duration of disease: 10 yrs Pre 18 Months10 Months
  • 18. Minimal Response Dose: 10 mg BID Duration of therapy: 7 mo Age: 61 Duration of disease: 5 yrs Pre Post
  • 19. No response Dose: 10 mg BID Duration of therapy: 7 mos Age: 55 Duration of disease: 7 yrs Pre Post
  • 20. Current dose: 5 mg BID Duration of therapy: 6 mos Age: 53 Duration of disease: 30 yrs Excellent response No response Pre Month 6Month 5
  • 21. What Happened? Month 5 Month 6 1. She lost coverage -> off Jak I for several weeks 2. Vit D was low 3. She was hypothyroid -> levothyroxine dose change
  • 22. Patien t # Se x Age at treatment initiation Disease duration (years since diagnosis of AA) Time since last hair growth (years) Months until first signs of hair growth Duration of therapy (months) Holding dose (mg/day, split twice daily) SALT score at treatment initiation SALT score at final data collection Percent regrowth at time of last appointme nt 1 F 50s 25 1 3 22 20 100 30.8 69% 2 F 40s 19 4 3 15 20 78.3 32.2 59% 3 F 20s 16 3 17 15 100 50.6 49% 4 F 50s 26 4 7 28 15 100 44.8 50% 5 F 30s 13 1 0 0.5 10 95 44 50% 6 F 50s 16 2 10 26 20 100 95 5% 7 F 60s 7 1 3 7 20 100 95 5% 8 F 40s 36 3 3 3 10 79.3 44.2 40% 9 F 50s 15 1 12 20 76 3 96% 10 F 30s 9 3 4 15 10 100 98 2% 11 F 50s 9 7 8 24 20 100 20 80% 12 F 50s 31 1 3 6 10 100 1 99% 13 F 50s 1 6 20 10 95 0 100% 14 F 30s 7 1 1 12 20 50 0 100% 15 F 50s 11 1 2 25 25 71.6 38 47% 16 M 20s 5 2 3 4 10 100 100 0% “scant” 17 M 50s 3 2 2 12 20 100 50 50% 18 F 50s 16 6 2 5 10 90 47.2 48% 19 F 40s 17 8 13 10 50 0 100% 20 F 60s 44 1 3 4 10 100 100 10%
  • 23. • 20 yo • Psoriasis and PsA
  • 24. 1 month 5 mg bid 5 month 10 mg bid 7 month 10 mg bid
  • 25. 10 months 15 mg bid Psoriasis improved Psoriatic arthritis persisted
  • 26. • 15 months • 15 mg bid • PsO/PsA flared • No change or disruption in dose • No obvious reason
  • 27. Durability with Long-Term Tofacitinib for AA • 6 patients experienced medication interruption • Adverse effect, illness, lapse in insurance coverage • 4/6 (66%) with medication interruption experienced shedding • Noted within 4 weeks • Resuming Tofacitinib after interruption had stabilization of shedding within 1-2 months • 2/20 discontinued due to adverse reactions
  • 28. Tolerability with Long-Term Tofacitinib for AA • LFT elevation (2/20) 10% • Resolved with dose adjustment in 1, the other had to stop tofa • Hypercholesterolemia (3/20) 15% • Noted by month 4 of treatment • Slower to respond with dose adjustment • Other: • Lower Extremity Edema (1/20) 5%: medication discontinued • Palpitations (1/20) 5%: found to be hyperthyroid • Leukopenia (1/20) 5%: transient • Herpes reactivation (1/20) 5% Safe but close monitoring (every 3-4 months) important
  • 29. Summary Tofacitinib Long Term Data • Results: - 75% achieved some regrowth - 60% - SALT50 - 25% - SALT90 (essentially fully regrowth) - 30-40% - insufficient or no response • Poor responders - Increase to 15-20 mg daily • Less likely to respond: - Longer duration of episode (>10 years) • Durability – 2 months post discontinuation – shedding
  • 30. Take Home Points • This is a very exciting time for alopecia areata! The era of biologic treatment of AA is just beginning - Future • More options- precision targeted therapy • Better • Safer • More affordable (hopefully) Support National Alopecia Areata Foundation (NAAF) Thank you!